Gilead Sciences Reports Strong Q3 Growth and Raises 2026 Base Business Guidance
Gilead Sciences reported exceptional third-quarter results, characterized by a 16% year-over-year increase in base business sales. This performance marks the company's strongest growth period in several years, driven by the breadth and durability of its current product portfolio. Looking ahead, management has raised its 2026 base business revenue guidance to a range of $30.7 billion to $31.0 billion. Additionally, the company provided long-term outlook details regarding Biktarvy, estimating a revenue impact of approximately $1.5 billion by 2028.
Tickers: $GILD
Topics: earnings report management commentary revenue growth